Dana-Farber's CAR T-Cell Therapy Shows Promise in Early Myeloma
Dana-Farber Cancer Institute has reported promising results from its phase 2 CAR-PRISM clinical trial, which tested CAR T-cell therapy in patients with high-risk smoldering multiple myeloma. The trial demonstrated durable remissions and deep eradication of malignant cells, with all treated patients achieving minimal residual disease negativity within two months post-infusion. The therapy, targeting B-cell maturation antigen, was administered before conventional chemotherapy, leveraging patients' intact immune systems for enhanced efficacy. 
